Related references
Note: Only part of the references are listed.A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species
Monique Verhaegen et al.
CANCER RESEARCH (2006)
The mitogen-activated protein kinase pathway can inhibit TRAIL-induced apoptosis by prohibiting association of truncated Bid with mitochondria
G. Ortiz-Ferron et al.
CELL DEATH AND DIFFERENTIATION (2006)
Tliptolide induces caspase-dependent cell death mediated via the mitochondfial pathway in leukemic cells
Bing Z. Carter et al.
BLOOD (2006)
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
K Kojima et al.
BLOOD (2005)
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
R Chen et al.
BLOOD (2005)
Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells
BZ Carter et al.
BLOOD (2005)
Mechanisms of resistance to TRAIL-induced apoptosis in cancer
LD Zhang et al.
CANCER GENE THERAPY (2005)
Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP
EH Kim et al.
ONCOGENE (2005)
Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells
YJ Lou et al.
LEUKEMIA RESEARCH (2005)
X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells
JM Cummins et al.
CANCER RESEARCH (2004)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Targeting death receptors in cancer with Apo2/TRAIL
SK Kelley et al.
CURRENT OPINION IN PHARMACOLOGY (2004)
Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL
R Ravi et al.
CANCER RESEARCH (2004)
Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation
R Rosato et al.
LEUKEMIA (2004)
Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics
DC McManus et al.
ONCOGENE (2004)
TRAIL and its receptors as targets for cancer therapy
H Yagita et al.
CANCER SCIENCE (2004)
Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity
AD Schimmer et al.
CANCER CELL (2004)
Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis
BZ Carter et al.
BLOOD (2003)
Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia
BZ Carter et al.
LEUKEMIA (2003)
PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2
S Frese et al.
ONCOGENE (2003)
Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma
H Okano et al.
LABORATORY INVESTIGATION (2003)
TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB
H Ehrhardt et al.
ONCOGENE (2003)
Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand
DT Jones et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Protein-based therapeutic approaches targeting death receptors
LE French et al.
CELL DEATH AND DIFFERENTIATION (2003)
Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-κB activation
KY Lee et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2002)
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression
S Fulda et al.
ONCOGENE (2002)
Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax
H LeBlanc et al.
NATURE MEDICINE (2002)
Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-κB activation in gastric cancer cells
XH Jiang et al.
ONCOGENE (2001)
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
K Ichikawa et al.
NATURE MEDICINE (2001)
Rel/NF-κB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1
D Bernard et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The kiss of death: promises and failures of death receptors and ligands in cancer therapy
PT Daniel et al.
LEUKEMIA (2001)
In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity
C Wuchter et al.
LEUKEMIA (2001)
Triptolide and chemotherapy cooperate in tumor cell apoptosis - A role for the p53 pathway
WT Chang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
p53-Independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-γ
RD Meng et al.
EXPERIMENTAL CELL RESEARCH (2001)
XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage
R Datta et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site
R Takimoto et al.
ONCOGENE (2000)
Share Paper
